Craft
  • Home
  •  / Karyopharm Therapeutics
Karyopharm Therapeutics

Karyopharm Therapeutics

Revenue

$209.8 M

FY, 2021

Karyopharm Therapeutics Summary

Company summary

Overview
Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1. Karyopharm is seeking the regulatory approval and commercialization of its lead drug candidate, selinexor (KPT-330), as a single orally administered agent in cancer indications with unmet clinical need, initially for hematologic malignancies. It is also advancing the clinical development of selinexor in multiple solid tumor indications. The Company has initiated three registration-directed trials in hematological cancers with selinexor and anticipates initiating a fourth registration-directed trial.
Type
Subsidiary
Founded
2008
HQ
Newton, MA, US | view all locations
Website
http://karyopharm.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Garen Bohlin
  • Richard Paulson

    Richard Paulson, President, Chief Executive Officer and Director

    • Brian Austad

      Brian Austad, Senior Vice President, Pharmaceutical Sciences

    • Sharon Shacham

      Sharon Shacham, Co-Founder, Chief Scientific Officer

    Operating MetricsView all

    Patents Issued

    10

    FY, 2015

    LocationsView all

    4 locations detected

    • Newton, MA HQ

      United States

      85 Wells Ave

    • Providence, RI

      United States

    • München, Bayern

      Germany

      9 Franziska-Bilek-Weg

    • Giv'atayim, Tel Aviv District

      Israel

      Ariel Sharon St 4

    Karyopharm Therapeutics Financials

    Summary financials

    Cash (Q2, 2022)
    $22.2M

    Footer menu